Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MorphoSys AG - American Depositary Shares (NQ: MOR )

18.96 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Dare Bioscience (NASDAQ:DARE) shares increased by 51.97% to $2.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino... 
From MorphoSys AG
Via AccessWire
Exposures Product Safety
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is... 
From MorphoSys AG
Via AccessWire
Exposures COVID-19 Product Safety
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of... 
From MorphoSys AG
Via AccessWire
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Barclays lowered Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) price target from $302 to $285. Vertex Pharmaceuticals shares fell 13.3% to $187.88 in pre-market trading.... 
Via Benzinga
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a... 
From MorphoSys AG
Via AccessWire
Exposures COVID-19 Product Safety
Why MorphoSys Stock Sank This Week
Investors weren't happy about the drugmaker's wheeling and dealing. 
Via The Motley Fool
Why Constellation Pharmaceuticals Stock Was Crushing It This Week
The small drugmaker is being acquired by MorphoSys. 
Via The Motley Fool
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide
Toward the end of trading Wednesday, the Dow traded up 0.05% to 34,594.18 while the NASDAQ fell 0.16% to 13,715.08. The S&P also rose, gaining 0.02% to 4,202.76. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
66 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) surged 95.2% to close at $62.55 on Wednesday amid renewed interest from retail investors. AMC Entertainment shares jumped... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Constellation (NASDAQ:CNST) shares rose 67.19% to $33.84 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 19.5... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 1%; iRhythm Technologies Shares Plunge
`Midway through trading Wednesday, the Dow traded up 0.33% to 34,689.77 while the NASDAQ rose 0.16% to 13,758.43. The S&P also rose, gaining 0.30% to 4,214.55. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Constellation Pharmaceuticals Stock Is Skyrocketing Today
The company is being acquired by MorphoSys. 
Via The Motley Fool
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares jumped 147.3% to $7.86 after the company provided an update on the overall survival (OS) data on its previously... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Advance Auto Parts Profit Tops Estimates
Following the market opening Wednesday, the Dow traded up 0.26% to 34,665.01 while the NASDAQ rose 0.15% to 13,757.62. The S&P also rose, gaining 0.23% to 4,211.85. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Lows On Wednesday
Before 10 a.m. ET on Wednesday, 8 companies hit new 52-week lows. Highlights: Dun & Bradstreet Hldgs (NYSE:DNB) was the biggest company by market cap to set a new 52-... 
Via Benzinga
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
Via Investor's Business Daily
Why Constellation Pharmaceuticals Is Soaring Today
Constellation Pharmaceuticals Inc (NASDAQ: CNST) is trading higher Wednesday morning after an announcement that MorphoSys AG (NASDAQ: MOR) will acquire the company. What Happened... 
Via Benzinga
MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma
MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Constellation (NASDAQ:CNST) shares moved upwards by 66.55% to $33.71 during Wednesday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation... 
From MorphoSys AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
MorphoSys to Acquire Constellation Pharmaceuticals
From MorphoSys AG
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2021
Upgrades Seaport Global upgraded the previous rating for Public Service Enterprise Group Inc (NYSE:PEG) from Neutral to Buy. Public Service Enterprise earned $1.28 in the... 
Via Benzinga
MorphoSys To Participate in UBS Global Healthcare Conference
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a... 
From MorphoSys AG
Via AccessWire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.